8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2014

Sigma-Aldrich Corporation

(Exact name of registrant as specified in charter)

Delaware	000-08135	43-1050617
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3050 Spruce Street, St. Louis, Missouri 63103

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (314) 771-5765

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2.):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 is a copy of the presentation to be used by Rakesh Sachdev, President and Chief Executive Officer of Sigma-Aldrich Corporation, at J.P. Morgan's 32nd Annual Healthcare Conference on Monday, January 13, 2014 in San Francisco, California. Mr. Sachdev will be speaking at 2:30 PM (Pacific) and interested parties may listen to his presentation via a live audio broadcast over the Internet available at http://investor.sigmaaldrich.com/. Users can click the "Webcast" icon to access this file.

The information in this Current Report on Form 8-K and the attached Exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Presentation to be used by Rakesh Sachdev, President and Chief Executive Officer of Sigma-Aldrich Corporation, at J.P. Morgan's 32nd Annual Healthcare Conference on Monday, January 13, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SIGMA-ALDRICH CORPORATION
Date:	January 13, 2014	By	/s/ George L. Miller
			George L. Miller General Counsel, Secretary & Senior VP

Exhibit Index

Exhibit No.	Description
99.1	Presentation to be used by Rakesh Sachdev, President and Chief Executive Officer of Sigma-Aldrich Corporation, at J.P. Morgan's 32nd Annual Healthcare Conference on Monday, January 13, 2014.

EX-99.1

J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2014 J.P. MORGAN HEALTHCARE CONFERENCE SIGMA-ALDRICH © 2014 Sigma-Aldrich Co. LLC. All rights reserved.

2 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CAUTIONARY STATEMENTS This presentation contains “forward-looking statements” regarding future sales, earnings, return on equity, return on invested capital, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see Item 1A of Part I of our latest Annual Report on Form 10-K and the first part of Item 2 of Part I to our latest Quarterly Report on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise. This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures used in this presentation, see the Appendix to this presentation – Reconciliation of GAAP to Non-GAAP Financial Measures.

3 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. RESEARCH APPLIED SAFC COMMERCIAL Discovery efforts in life science and material science research Clinical and environmental diagnostics Industrial applications Pharma and electronics manufacturing OUR PURPOSE The trusted and preeminent global provider to the research laboratory, targeted applied and commercial markets ENABLING SCIENCE TO IMPROVE THE QUALITY OF LIFE A global leader in chemicals, biochemicals, kits and services for scientific discovery, development, manufacturing and diagnostics

4 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CONSTANT AND CONSISTENT PURPOSE HAS DRIVEN THE COMPANY that will make the world a safer, cleaner, and healthier place 160+ COUNTRIES $2.7B* SALES REVENUE 1.4M INDIVIDUAL CUSTOMERS >215K PRODUCTS & SERVICES SOLUTIONS By inspiring customer innovations and solutions Sigma-Aldrich enables science to improve the quality of life. *Last twelve months ended 9/30/13.

5 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED, GLOBALLY BALANCED 52% 23% 25% SAFC COMMERCIAL BUSINESS UNIT Life Science Products Life Science Services Hitech APPLIED BUSINESS UNIT Diagnostics and Testing Industrial Applications RESEARCH BUSINESS UNIT Academic, Government and Hospitals Pharmaceutical Dealers ASIA PACIFICEUROPE MIDDLE EAST AFRICA AMERICAS % OF GLOBAL SALES* 43% 38% 19% *Last twelve months sales ended 9/30/13.

6 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. 2013 HIGHLIGHTS Realigned into 3 Customer-Facing Business Units *Last twelve months sales ended 9/30/13. HONORED FOR GLOBAL CITIZENSHIP DOW JONES SUSTAINABILITY INDEX, CIVIC 50, CDP GLOBAL 500, CLIMATE DISCLOSURE LEADERSHIP INDEX (CDLI) DELIVERED STRONG PERFORMANCE IN SALES, PROFITS & FREE CASH FLOW* STRENGTHENED ALIGNMENT WITH CUSTOMERS AND INCREASED COMPLETE SOLUTION OFFERINGS RESEARCH APPLIED SAFC COMMERCIAL Reagents and consumables to Pharmaceutical/Biotechnology and non-profit research organizations Solutions and critical raw materials for testing in clinical and industrial applications Customized manufacturing materials and services for small and large molecule drugs and advanced materials

7 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. MISSION: ADDRESSABLE MARKETS: LTM SALES (ENDED 9/30/13): Enabling scientific research to discover and develop new drugs and materials • Markets defined as chemicals, reagents and kits • Fragmented markets, diverse mature Life Science Tools companies LEADING eCOMMERCE PLATFORM: > 55% of sales conducted via Web > 57M website visits/year RESEARCH BUSINESS UNIT ~$16B No one product >1% sales / No one customer >2% sales Source: Industry reports, LPA, SIAL Analysis ~$1.4B Academic, Government, Hospitals Pharmaceutical/Biotechnology and CROs Dealers ~50% ~25% ~25% BIOLOGICAL AND CHEMICAL REAGENTS CONSUMABLES AND SMALL APPARATUS UNPARALLELED PRODUCT PORTFOLIO: >215,000 33 WORLDWIDE DISTRIBUTION CENTERS 35% 39% 26% AMERICAS EMEA ASIA PACIFIC GLOBAL SALES PRESENCE

8 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. RESEARCH MARKET TRENDS Large Pharma R&D Consolidation U.S. Academic Funding Constraints Collaborations eCommerce Translational Research Emerging Markets ~5% 52% RESEARCH ~9% US ACADEMICLARGE PHARMA RESEARCH % OF SIGMA-ALDRICH GLOBAL SALES Sales of Research Products to large Pharma make up ~5% of all Sigma-Aldrich sales

9 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. STRONG POSITION IN LARGE PHARMA RESEARCH LARGE STRATEGIC CUSTOMERS SIGMA-ALDRICH PRESENCE 2 LARGEST DISTRIBUTORS A l l B l l C l l D l l E l l F l l G l l l H l l I l l J l l K l l L l l M l l N l l SIGMA-ALDRICH KEY DIFFERENTIATORS • Product breadth and availability • Quality, reproducibility and world-class technical support • Global reach • Bench to bulk ~5% 52% RESEARCH LARGE PHARMA RESEARCH 25% 23% As consolidation continues, customers and suppliers have heightened awareness of channel access to product, availability and technical service

10 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. SIGMA-ALDRICH.COM #1 IN LIFE SCIENCE ECOMMERCE SALES* VISITS ORDERS ~$1B 67M 2.6M Source: coremetrics & BI, Alexa Pro, Normalized to SIAL Coremetrics 30% 36% 34% ASIA PACIFIC EUROPE, MIDDLE EAST, AFRICA AMERICAS WEB TRAFFIC BY REGIONAVERAGE UNIQUE VISITORS PER MONTH 0 40 60 80 100 20 SIGMA-ALDRICH COMPETITOR 1 COMPETITOR 2 COMPETITOR 3 COMPETITOR 4 *Last twelve months sales ended 9/30/13.

11 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED RESEARCH SALES GAIN TRACTION IN 2013 ACADEMIC PHARMA DEALERS VALUE PROPOSITION Enabling scientists to innovate, conduct and publish quality research through breadth of scientific products and collaborations Accelerating drug development with breadth of scientific products and customized solutions Expanding access to new customers and geographies through commercially optimized channel 2013 INITIATIVES • Translational Research with focus on drug discovery workflow solutions • Sales and Marketing alignment to key customer segments • Scientific collaborations to drive innovation • Enterprise solutions for strategic accounts - Supply chain integration - Chemical sourcing • Address growing Biotech segment • Dealers as Partners Program • Channel expansion • Increased presence in Latin America, Middle East and Africa 2013 SUCCESS • Scripps collaboration • Positive results of drug discovery focus in Academia • Gained traction with account management focus in Europe and US • Growing Research services-based solutions (e.g., Aldrich Market Select) • Five consecutive quarters of improved organic sales growth through Q3 2013 • Formalized dealer partnerships globally • Strong growth in emerging regions: Eastern Europe, Middle East and Africa

12 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 RESEARCH ORGANIC SALES GROWTH LONG-TERM EXPECTATIONS Low to Mid Single Digit *Provided on Oct 2013 Q3 conference call (Mid Single Digit) (Low Single Digit) Low Single Digit Mid Single Digit High Single Digit Q1-13 Q2-13 Q3-13 DEALERS PHARMA ACADEMIC 2013 Research organic sales growth guidance* of low single digit; improving sequential quarterly performance in 2013

13 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. MISSION: LTM SALES (ENDED 9/30/13): Supply customized solutions and critical components and materials to diagnostic companies, testing laboratories and industrial companies APPLIED MARKETS ARE LARGE AND GROWING APPLIED BUSINESS UNIT Diagnostics and Testing Industrial ~50% ~50% BROAD AND INNOVATIVE PORTFOLIO OF: • High quality components and kits • Reagents • Consumables • Critical raw materials • Standard and certified reference materials $0.6B Both customer and supplier base are fragmented. Source: Industry Reports and Team Analysis DIAGNOSTICS INDUSTRIAL INDUSTRIAL MATERIALS $34B MID–HIGH SINGLE DIGIT $35B LOW –MID SINGLE DIGIT $16B MID SINGLE DIGIT

14 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. APPLIED MARKET SEGMENTS Applied markets are large and growing with solid underlying macroeconomic growth fundamentals Source: Frost & Sullivan, Kalorama; Strategic Directions International Report DIAGNOSTIC MANUFACTURERS DIAGNOSTIC AND FORENSIC TESTING FOOD & BEVERAGE AND ENVIRONMENTAL TESTING AGRICULTURE & BIOTECHNOLOGY CHEMICAL MANUFACTURING CONSUMER PRODUCTS APPROX. SIZE $1B $35B $2B $9B $9B $21B GROWTH High Single High Single Mid Single Mid Single Mid Single Mid Single CURRENT PRODUCT OFFERINGS • Raw Materials • Lab Essentials • Standards/CRM • Oligos • Enzymes • Sample Prep • LC/GC Columns • Standards/CRM • Sample Prep • LC/GC Columns • Standards/CRM • Lab Essentials • Lab Essentials • Genomics • Analytical Consumables • Raw Materials • Lab Essentials • Chemical Synthesis • Materials Science • Procurement Services • Raw Materials (F&F) • Sample Prep • LC/GC • Lab Essentials

15 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED APPLIED SALES GAINING TRACTION DIAGNOSTIC & TESTING LABS INDUSTRIAL VALUE PROPOSITION Providing products ranging from raw materials and basic research reagents to components and assays to perform tests, including analytical standards Targeting certain industrial segments with specific raw materials and solutions to meet customer needs 2013 INITIATIVES • Implemented segment specific, strategic marketing programs • Implemented rapid response team consisting of commercial and scientific expertise • Built stronger capabilities to assess and execute OEM opportunities for diagnostics companies • Aligned sales functions to support new opportunities • Implemented global account management structure for top industrial customers • Aligned R&D resources to strategic markets such as agbio and medical materials 2013 SUCCESS • Separation technology for cancer testing • Stable Isotope components for ulcer testing and cancer detection • Elite products for diagnostic kits • Expansion of ISO 13485 manufacturing capabilities • Globally expanded standards and certified reference materials • Expanded offering of high-quality enzymes for diagnostics use • Generated traction with new customers in agbio, medical devices and personal care products • Sales of kits for workplace air monitoring

16 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 APPLIED ORGANIC SALES PERFORMANCE LONG-TERM EXPECTATIONS Mid –High Single Digit 2013 Applied organic sales growth guidance* of mid single digit *Provided on Oct 2013 Q3 conference call (Mid Single Digit) (Low Single Digit) Low Single Digit Mid Single Digit High Single Digit Q1-13 Q2-13 Q3-13 INDUSTRIAL DIAGNOSTICS & TESTING

17 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. LTM SALES (ENDED 9/30/13):MISSION: To develop and manufacture products and services solutions for the commercial production of our Pharma, BioPharma and Electronics customers SAFC COMMERCIAL BUSINESS UNIT ~$0.7B Life Science Products Life Science Services Hitech Electronics ~65% ~20% ~15% TARGET MARKETS ARE LARGE AND GROWING TOUGH TO MAKE, CRITICAL TO PERFORMANCE OFFERINGS • Custom offerings to build a unique position with customers • Difficult to replicate or substitute • Typically small percentage of total cost of customer’s final product • Industrial cell culture media • Active API • Intermediates • Raw materials • Biological testing services Organometallic precursors for LEDs and semiconductors LIFE SCIENCE MID SINGLE DIGIT $55B $5B+ ELECTRONICS ~10% (BUT CYCLICAL) Source: Industry Reports and Team Analysis

18 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. VALUE PROPOSITION High quality products and services solutions which are tough to make, difficult to replicate, critical to performance of our customers’ products and processes and represent small portion of their cost 2013 INITIATIVES • Resource allocation to Top 100 customers • Selective capabilities and manufacturing capacity addition • Increased supply chain quality, transparency and risk mitigation initiatives 2013 SUCCESS • Strong growth in Life Sciences segment: cell culture media and contract manufacturing services, BioReliance biotesting and toxicology services • Strong Growth in Hitech in chemical precursors for advanced semiconductors chips • Strategic Account Program elevating enterprise relationship • Expansion of our quality initiatives and risk mitigation activities like Pharmagrade products • Continued strong demand in High Potency and Antibody Drug Conjugate capabilities SAFC COMMERCIAL BUSINESS UNIT LIFE SCIENCES AND HITECH ELECTRONICS

19 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SAFC COMMERCIAL OFFERINGS ENABLING CUSTOMERS TO MANUFACTURE DRUGS AND MATERIALS BUSINESS UNIT SEGMENTS BUSINESS UNIT INITIATIVES DESCRIPTION 2013 SAFC SALES* CUSTOMER MARKETS Biological Drugs Small Molecule Drugs LEDs Semiconductors Energy/Display Life Science Products Biopharma Materials Critical raw materials for biological drugs ~65% l Pharma Materials Critical raw materials for small molecules l Contract Manufacturing Services cGMP Intermediates and APIs for small molecules and biological drugs l l Life Science Services Biopharma Services Biologic testing services & viral manufacturing services ~20% l Early Development Services Genetic & mammalian toxicology Solid state services l Hitech Electronics Hitech Electronics Precursors for LED & semiconductors Performance materials for energy & display ~15% l SAFC COMMERCIAL M ARKE TS *Last twelve months sales ended 9/30/13.

20 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SAFC COMMERCIAL EXPANSION ACTIVITIES LIFE SCIENCE PRODUCTS LIFE SCIENCE SERVICES HITECH ELECTRONICS • Expanding dry powder media capacity in Scotland • Expanding high potency API capacity in Wisconsin • Expanding commercial conjugation capacity in St. Louis • Increased synergies with BioReliance • Opened high complexity protein characterization laboratories • New clearance services laboratories in US • Increased capacity utilization of plant in Taiwan

21 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 SAFC COMMERCIAL ORGANIC SALES PERFORMANCE (Double Digit) (Mid Single Digit) Low Single Digit Mid Single Digit (High Single Digit) Double Digit (Low Single Digit) High Single Digit Q1-13 Q2-13 Q3-13 LIFE SCIENCE SERVICES LIFE SCIENCE PRODUCTS HITECH LONG-TERM EXPECTATIONS Mid–High Single Digit 2013 SAFC Commercial organic sales growth guidance* of mid single digit *Provided on Oct 2013 Q3 conference call

22 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. LONG-TERM ORGANIC SALES GROWTH ORGANIC SALES GR OW TH RESEARCH Low–Mid Single Digit Mid–High Single Digit Mid–High Single Digit APPLIED COMMERCIAL OVERALL ≥ ~Mid Single Digit

23 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. SIGMA-ALDRICH OUTLOOK TO INCREASING SHAREHOLDER VALUE ORGANIC SALES GROWTH ≥ ~Mid Single Digit MARGIN EXPANSION OF CORE BUSINESS ~50 bps per Year ASSET MANAGEMENT M&A SHAREHOLDER VALUE HIGH ROIC HIGH FREE CASH FLOW

24 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. ORGANIC SALES GROWTH ≥ ~MID SINGLE DIGITS SG&A LEVERAGE GROSS MARGIN EXPANSION New Global Supply Chain organization Manufacturing footprint Logistics and distribution Productivity and quality improvements Expense growth < organic sales growth LEVERS TO EXPAND MARGINS Goal of 50 bps/yr expansion in margins on core business

25 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. 2013: ANOTHER YEAR OF SOLID CASH FLOW GROWTH ON TRACK TO EXCEED $450M FREE CASH FLOW TOTAL DEBT 9/30/13 $414M TOTAL CASH 9/30/13 $688M ROIC 20% 9/30/13

26 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. USES OF CASH INCREASING EPS AND DIVIDENDS FOR 38 CONSECUTIVE YEARS INVESTED CAPITAL EXPENDITURES REPURCHASED OF STOCK $1.5B$940M IN DIVIDENDS $700M DISTRIBUTED TO ACQUIRE 14 COMPANIES $1.2B INVESTED SINCE 2004:

27 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. ORGANIC AND INORGANIC INVESTMENTS INCREASED SHAREHOLDER VALUE $90 $80 $70 $60 $50 $40 $30 $20 $10 $0 $100 2004 2006 2008 2010 2004 Tetrionics, Ultraf_ine Acquired 2005 Proligo Group, JRH Biosciences Acquired 2006 Bejing Superior, Iropharm Acquired 2007 $2BN SALES | 7,900 EMPLOYEES 36 COUNTRIES | 130,000 PRODUCTS Pharmorphix , Epichem Group Ltd., Molecular Medicine Bioservices, Inc. Acquired 2009 ChemNavigator.com, Inc. Acquired 2010 Cerilliant Corporation Acquired BioReliance Holdings, Inc., Research Organics Inc. Acquired Wuxi, China Packaging And QC Facility Opens Bangalore, India Distribution and Packaging Facility Opens 2011 Vetec Quimica Fina, Ltda. Acquired 2012 2012 Sigma-Aldrich Corporation (SIAL) $2.6BN SALES | 9,000 EMPLOYEES 40 COUNTRIES | 175,000 PRODUCTS Share Price Creating shareholder value through internal investments, M&A and operational excellence

28 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH A WORLD-CLASS ORGANIZATION Well-positioned for the future Exceptional SCIENTIFIC KNOWLEDGE Superior QUALITY and COMPLIANCE First-Class Customer SERVICE Extensive SELECTION of Products and Services Established TRUST with Our Stakeholders Market-leading INNOVATION